Study of the incidence of metabolic syndrome and related factors in patients with hypoglycemia: a cr
Recently, global medical institutions and public health systems have continued to advance service capacity building to provide stronger guarantees for public health. Systemic Lupus Erythematosus (SLE) has also been linked to the development of metabolic syndrome (Metabolic Syndrome, MetS). In order to determine the incidence of metabolic syndrome and identify its associated factors, this study began in January 2024 and ended in December 2025.
A total of 427 adults were diagnosed with SLE and were recruited for continuous sampling. Using IBM SPSS Statistics for Windows, Version 25. 0 (released on January 30, 2017, by IBM Corporation, Anchorage, New York, U.
S. ) these adults collected and analyzed demographic, clinical, biochemical, and disease-related data. Classification variables were compared using chi-square tests, continuous variables were compared using independent sample t tests, and the factors associated with MetS were identified using multi-variable logical regression.
Among 427 SSLE patients, 39. 34% met MetS diagnostic criteria. The most common metabolic indicator components were low-density lipoprotein cholesterol (HDL-C), central obesity, hypertension, hyperglycemia, and hyperglycemia.
In the logistic regression analysis of multiple variables, the older the age, the obese, the BMI ≥ 30 kg/m² The greater the duration of the disease, the longer the family history of autoimmune diseases, the greater the risk of corticosteroid use with MetS, and the greater the risk of use of hydroxychloroquine with MetS. MetS is common in rheumatoid arthritis (SLE) patients and is associated independently with the following factors: 1 age: MetS is age-related; 2 gender: MetS is more common in female SLE patients; 3 race: MetS is more common in non-white SLE patients; 4 genetics: MetS is more common in genetically related SLE patients; 5 lifestyle: MetS is more common in lifestyle-related SLE patients; 6 factors: MetS is more common in other factors related SLE patients. These findings reiterate the importance of routine metabolic screening and comprehensive metabolic abnormalities assessment as an important part of the clinical management of SLE patients.
Considering that the correlations observed in the cross-structural design of the study should not be interpreted as causal, and that it is necessary to clarify the time relationship and validate the predictability of these findings along the study.
